Table 2.
Univariate and multivariate analyses of the factors between groups by the pattern of postablation whole body scan
| Variables | Negative midline uptake (n = 101) | Positive midline uptake (n = 149) | Univariate | Multivariate | |
|---|---|---|---|---|---|
| P value | P value | OR (95 % CI) | |||
| Age (years) | 47.02 ± 12.55 | 48.38 ± 11.51 | 0.377 | ||
| Gender | |||||
| Female | 78 (77.2 %) | 101 (67.8 %) | |||
| Male | 23 (22.8 %) | 32.2 (32.2 %) | 0.117 | 0.166 | |
| T stage | |||||
| T1 | 58 (57.4 %) | 81 (54.4 %) | |||
| T2 | 2 (2.0 %) | 2 (1.3 %) | |||
| T3 | 30 (29.7 %) | 51 (34.2 %) | |||
| T4 | 11 (10.9 %) | 15 (10.1 %) | 0.879 | ||
| Multiplicity | |||||
| Solitary | 54 (53.5 %) | 79 (53.0 %) | |||
| Multiple | 47 (46.5 %) | 70 (47.0 %) | 1.000 | ||
| Bilaterality | |||||
| Unilateral | 71 (70.3 %) | 97 (65.1 %) | |||
| Bilateral | 30 (29.7 %) | 52 (34.9 %) | 0.413 | ||
| N stage | |||||
| N0 | 7 (6.9 %) | 22 (14.8 %) | |||
| N1a | 76 (75.2 %) | 111 (74.5 %) | |||
| N1b | 18 (17.8 %) | 16 (10.7 %) | 0.067 | 0.165 | |
| Tumor size (mm) | |||||
| < 10 | 47 (46.5 %) | 80 (53.7 %) | |||
| ≥ 10 | 54 (53.5 %) | 69 (46.3 %) | 0.303 | ||
| Dose of administered 131I (GBq) | |||||
| 3.70 | 60 (59.4 %) | 78 (52.3 %) | |||
| 5.55 | 4 (4.0 %) | 14 (9.4 %) | |||
| 6.66 | 37 (36.6 %) | 57 (38.3 %) | 0.217 | 0.804 | |
| Interval between operation and RAI therapy (days) | 102.63 ± 18.02 | 101.52 ± 16.91 | 0.620 | ||
| Pre-ablation Tg (ng/mL)* | 1.71 ± 2.38 | 1.98 ± 2.20 | 0.363 | ||
| Pre-ablation TgAb (U/ml)* | 26.24 ± 10.65 | 25.61 ± 10.33 | 0.642 | ||
| Pre-ablation TSH (μIU/ml)* | 81.00 ± 30.12 | 78.86 ± 29.88 | 0.581 | ||
| Post-ablation Tg (ng/mL)† | 8.12 ± 11.05 | 34.12 ± 54.31 | < 0.001 | < 0.001 | 1.060 (1.028–1.092) |
| Post-ablation TgAb (U/ml)† | 27.06 ± 12.21 | 25.05 ± 10.95 | 0.175 | 0.107 | |
| Post-ablation TSH (μIU/ml)† | 38.08 ± 30.84 | 38.06 ± 31.07 | 0.996 | ||
| Tg ratio‡ | 7.81 ± 8.98 | 20.01 ± 19.84 | < 0.001 | 0.001 | 1.059 (1.023–1.096) |
OR odds ratio, CI confidence interval, Tg thyroglobulin, TgAb anti-thyroglobulin antibody, TSH thyroid-stimulating hormone
*Pre-ablation Tg, TgAb, and TSH were measured just before I-131 ablation therapy
†Post-ablation Tg, TgAb, and TSH were measured 7 days after oral administration of I-131
‡Tg ratio was defined as ‘post-ablation Tg devided by pre-ablation Tg’